98%
921
2 minutes
20
Introduction: Actinic keratoses (AKs) are rough, scaly patches from UV exposure, increasing the risk of non-melanoma skin cancer (NMSC). This study examines AK incidence in Korea and its role as a risk factor for NMSC.
Methods: A retrospective nationwide register-based cohort study analyzed 2,917 AK patients and 14,585 controls from 2002 to 2019. Patients diagnosed with AK were followed until NMSC occurrence, death, emigration, or December 2019.
Results: AK incidence reached 44.8 per 100,000 person-years in 2019. The adjusted hazard ratio for NMSC in AK patients was 8.91 (95% confidence interval, 5.72-13.90). Higher NMSC risk was observed in female AK patients, those under 60 years, and those with lower income levels. The 16-year cumulative incidence of NMSC was 4.19% in AK patients versus 0.44% in controls.
Conclusion: AK significantly increases the risk of NMSC in Koreans, highlighting the need for tailored surveillance and treatment strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651322 | PMC |
http://dx.doi.org/10.1159/000539878 | DOI Listing |
Int J Cancer
September 2025
Radiation Effects Department, UK Health Security Agency (UKHSA), Harwell Campus, Oxfordshire, UK.
This study presents the most comprehensive evaluation to date of non-melanoma skin cancer (NMSC) risk in the UK National Registry for Radiation Workers, examining separately both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The cohort includes 172,452 workers with over 5.3 million person-years of follow-up (1955-2011) and a mean cumulative dose of 24.
View Article and Find Full Text PDFWorld J Transplant
September 2025
Division of Gastroenterology, Tristar Centennial Medical Center, Nashville, TN 37203, United States.
Liver transplantation (LT) is the definitive treatment for end-stage liver disease, acute liver failure, and liver cancer. Although advancements in surgical techniques, postoperative care, and immunosuppressive therapies have significantly improved outcomes, the long-term use of immunosuppression has increased the risk of complications, including infections, cardiovascular disease, and cancer. Among these, malignancies (DNMs) are a major concern, accounting for 20%-25% of deaths in LT recipients surviving beyond the early post-transplant period.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Dermatology Department, Hospital Universitario Ramon y Cajal, Carretera M-607 km 9.1, 28034 Madrid, Spain.
Photodynamic therapy (PDT) has become a widely used modality for treating actinic keratosis (AK) and non-melanoma skin cancers (NMSC), as well as other inflammatory or infectious diseases. Despite its efficacy, limitations such as incomplete responses and pain have motivated the exploration of protocol enhancements. This review examines the clinical and biological rationale for light fractionation-dividing the total light dose into two separate exposures with a dark interval-as a strategy to improve PDT outcomes.
View Article and Find Full Text PDFCancers (Basel)
August 2025
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
The relationship between occupational sun exposure and melanoma risk is complex and multifaceted, with existing evidence yielding contradictory findings. Unlike Non-Melanoma Skin Cancer (NMSC), for which occupational sun exposure is a well-established risk factor, the link with cutaneous melanoma remains contentious. This study aimed to evaluate whether, in a cohort of patients with cutaneous melanoma, an association existed between occupational sun exposure and melanoma, specifically with histotype, site of occurrence, and Breslow index.
View Article and Find Full Text PDFBMC Nephrol
August 2025
Department of Internal Medicine, King Khalid University College of Medicine, Abha, Saudi Arabia.
Non-melanoma skin cancer is a prevalent complication in renal transplant recipients due to long-term immunosuppressive therapy. Calcineurin inhibitors, such as tacrolimus and cyclosporine, are effective in preventing graft rejection; however, they significantly increase the risk of non-melanoma skin cancer through broad immunosuppressive and pro-oncogenic mechanisms. Belatacept, a selective co-stimulation blocker targeting the CD80/CD86-CD28 axis, has emerged as a mechanistically distinct alternative with potential benefits for oncologic and renal outcomes.
View Article and Find Full Text PDF